PDS Biotech Closes $11.3M Initial Tranche of Nant-Led PIPE, Redeems Yorkville Note
PDSB sits 94% above its 52-week low of $0.195 on elevated volume (6.0× avg).
Summary
PDS Biotech closed the first $11.3 million tranche of its Nant Capital-led PIPE, redeemed its Yorkville note for $4.6 million, and seated two Nant-affiliated directors.
Key Events · Financing and Capital Events · PDSB
-
Initial PIPE Closing
Completed initial closing of the Nant Capital-led PIPE with gross proceeds of approximately $11.3 million at $0.2825 per share unit.
-
Securities Issued
Issued 16,502,870 common shares, 23,498,156 pre-funded warrants, and 20,000,514 common warrants, creating substantial potential dilution.
-
Yorkville Note Redeemed
Redeemed the Yorkville promissory note in full for approximately $4.6 million, eliminating the 10% interest debt obligation.
-
Board Appointments
Dr. Patrick Soon-Shiong and James Banaag joined the board effective at closing; board waived Nasdaq independence requirement for Nant designees.
Analysis · PDSB · Life Sciences
A critical capital infusion has been secured with the initial closing of the Nant Capital-led PIPE, raising $11.3 million in gross proceeds at $0.2825 per share unit — a lifeline for a company with only $5.6 million in cash and a going concern warning. The Yorkville promissory note was also redeemed in full for $4.6 million, eliminating a 10% interest debt obligation. The securities issued include 16.5 million common shares, 23.5 million pre-funded warrants, and 20 million common warrants, creating substantial potential dilution. Effective at closing, Dr. Patrick Soon-Shiong and James Banaag joined the board, with the board waiving Nasdaq independence requirements for the Nant designees. The milestone closing could add another $11 million if PDS0301 reaches a Phase 3 protocol submission.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.2M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.